March 31 (Reuters) - Genocea Biosciences Inc
* Positive 12 month efficacy data from its phase 2 dose optimization trial evaluating gen-003 for treatment of genital herpes
* Consistent efficacy across potential phase 3 clinical trial endpoints
* Anticipate reporting virologic efficacy data for gen-003 from our recently-initiated phase 2b study in q3 of 2016
* Anticipate reporting clinical efficacy data at 6 months post dosing around end of 2016 for gen-003 from recently-initiated phase 2b study
* Anticipate conducting end of phase 2 meeting with fda in q1 of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)
Our Standards: The Thomson Reuters Trust Principles.